Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1921 1
1948 1
1950 1
1951 1
1953 1
1954 1
1955 2
1956 1
1957 1
1958 1
1959 1
1960 2
1961 8
1962 10
1963 4
1964 8
1965 7
1966 7
1967 10
1968 11
1969 13
1970 13
1971 16
1972 9
1973 5
1974 13
1975 26
1976 29
1977 40
1978 17
1979 32
1980 47
1981 36
1982 28
1983 57
1984 41
1985 40
1986 35
1987 56
1988 69
1989 71
1990 89
1991 91
1992 108
1993 109
1994 91
1995 83
1996 86
1997 94
1998 118
1999 103
2000 123
2001 146
2002 163
2003 163
2004 205
2005 205
2006 210
2007 231
2008 265
2009 243
2010 230
2011 299
2012 313
2013 306
2014 305
2015 334
2016 333
2017 412
2018 616
2019 750
2020 1049
2021 1156
2022 1180
2023 1155
2024 668

Text availability

Article attribute

Article type

Publication date

Search Results

11,302 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Bozorgpanah
Page 1
Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics.
Ramasamy T, Ruttala HB, Munusamy S, Chakraborty N, Kim JO. Ramasamy T, et al. J Control Release. 2022 Dec;352:861-878. doi: 10.1016/j.jconrel.2022.10.050. Epub 2022 Nov 14. J Control Release. 2022. PMID: 36397636 Review.
An increasing number of ASO-based therapeutics is being tested in clinical trials. Improvements to the delivery of ASO drugs could potentially change the therapeutic landscape for many conditions in the near future. This review describes the technological advances a …
An increasing number of ASO-based therapeutics is being tested in clinical trials. Improvements to the delivery of ASO drugs c …
ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth.
Ma WK, Voss DM, Scharner J, Costa ASH, Lin KT, Jeon HY, Wilkinson JE, Jackson M, Rigo F, Bennett CF, Krainer AR. Ma WK, et al. Cancer Res. 2022 Mar 1;82(5):900-915. doi: 10.1158/0008-5472.CAN-20-0948. Cancer Res. 2022. PMID: 34921016 Free PMC article.
Here, we explore the potential of ASO-based PKM splice switching as a targeted therapy for liver cancer. ...This PKM isoform switch increased pyruvate-kinase activity and altered glucose metabolism. In an orthotopic HCC xenograft mouse model, the lead ASO and a seco …
Here, we explore the potential of ASO-based PKM splice switching as a targeted therapy for liver cancer. ...This PKM isoform switch i …
Drug Discovery Perspectives of Antisense Oligonucleotides.
Kim Y. Kim Y. Biomol Ther (Seoul). 2023 May 1;31(3):241-252. doi: 10.4062/biomolther.2023.001. Epub 2023 Mar 2. Biomol Ther (Seoul). 2023. PMID: 36859811 Free PMC article. Review.
Since the emergence of the concept of ASOs in 1978, it took more than 20 years before they were developed into drugs for commercial use. Nine ASO drugs have been approved to date. However, they target only rare genetic diseases, and the number of chemistries and mechanisms …
Since the emergence of the concept of ASOs in 1978, it took more than 20 years before they were developed into drugs for commercial use. Nin …
Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Alhamadani F, Zhang K, Parikh R, Wu H, Rasmussen TP, Bahal R, Zhong XB, Manautou JE. Alhamadani F, et al. Drug Metab Dispos. 2022 Jun;50(6):879-887. doi: 10.1124/dmd.121.000418. Epub 2022 Feb 27. Drug Metab Dispos. 2022. PMID: 35221289 Free PMC article. Review.
The market for large molecule biologic drugs has grown rapidly, including antisense oligonucleotide (ASO) drugs. ASO drugs work as single-stranded synthetic oligonucleotides that reduce production or alter functions of disease-causing proteins through various mechan …
The market for large molecule biologic drugs has grown rapidly, including antisense oligonucleotide (ASO) drugs. ASO drugs wor …
Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Migliorati JM, Liu S, Liu A, Gogate A, Nair S, Bahal R, Rasmussen TP, Manautou JE, Zhong XB. Migliorati JM, et al. Drug Metab Dispos. 2022 Jun;50(6):888-897. doi: 10.1124/dmd.121.000417. Epub 2022 Feb 27. Drug Metab Dispos. 2022. PMID: 35221287 Free PMC article. Review.
The ADME of ASO drugs contributes to their unique set of ADRs and toxicity. ...This knowledge is useful for discovery and development of new ASO drugs as well as clinical use of current FDA-approved ASO drugs....
The ADME of ASO drugs contributes to their unique set of ADRs and toxicity. ...This knowledge is useful for discovery and development …
Antisense oligonucleotide therapy for KCNT1 encephalopathy.
Burbano LE, Li M, Jancovski N, Jafar-Nejad P, Richards K, Sedo A, Soriano A, Rollo B, Jia L, Gazina EV, Piltz S, Adikusuma F, Thomas PQ, Kopsidas H, Rigo F, Reid CA, Maljevic S, Petrou S. Burbano LE, et al. JCI Insight. 2022 Dec 8;7(23):e146090. doi: 10.1172/jci.insight.146090. JCI Insight. 2022. PMID: 36173683 Free PMC article.
After a single intracerebroventricular bolus injection of a Kcnt1 gapmer ASO in symptomatic mice at postnatal day 40, seizure frequency was significantly reduced, behavioral abnormalities improved, and overall survival was extended compared with mice treated with a control …
After a single intracerebroventricular bolus injection of a Kcnt1 gapmer ASO in symptomatic mice at postnatal day 40, seizure frequen …
Na(3)Al(AsO(4))(2).
Fakhar Bourguiba N, Zid MF, Driss A. Fakhar Bourguiba N, et al. Acta Crystallogr Sect E Struct Rep Online. 2013 Feb 1;69(Pt 2):i14. doi: 10.1107/S1600536813002213. Epub 2013 Jan 31. Acta Crystallogr Sect E Struct Rep Online. 2013. PMID: 23424394 Free PMC article.
The structure of the title compound tris-odium aluminium bis-(arsenate), Na(3)Al(AsO(4))(2), is built up from AlO(4) and AsO(4) corner-sharing tetra-hedra, forming an undulating two-dimensional framework parallel to (100). The layers are constituted of large Al(6)As …
The structure of the title compound tris-odium aluminium bis-(arsenate), Na(3)Al(AsO(4))(2), is built up from AlO(4) and AsO(4 …
AgNa(2)Mo(3)O(9)AsO(4).
Hamza H, Zid MF, Driss A. Hamza H, et al. Acta Crystallogr Sect E Struct Rep Online. 2011 Nov;67(Pt 11):i63. doi: 10.1107/S1600536811041961. Epub 2011 Oct 22. Acta Crystallogr Sect E Struct Rep Online. 2011. PMID: 22219728 Free PMC article.
The title compound, silver disodium trimolybdenum(VI) nonaoxide arsenate, AgNa(2)Mo(3)O(9)AsO(4), was prepared by a solid-state reaction at 808 K. The structure consists of an infinite (Mo(3)AsO(13))(n) ribbon, parallel to the c axis, composed of AsO(4) tetra …
The title compound, silver disodium trimolybdenum(VI) nonaoxide arsenate, AgNa(2)Mo(3)O(9)AsO(4), was prepared by a solid-state react …
A mu-AsO(4)-Bridging Hexadecanuclear Ni-Substituted Polyoxotungstate.
Lian C, Li HL, Yang GY. Lian C, et al. Inorg Chem. 2021 Mar 15;60(6):3996-4003. doi: 10.1021/acs.inorgchem.1c00056. Epub 2021 Feb 25. Inorg Chem. 2021. PMID: 33630580
A novel tetrahedral mu-AsO(4)-bridging hexadecanuclear Ni-substituted silicotungstate (ST) Na(21)H(10)[(AsO(4)){Ni(8)(OH)(6)(H(2)O)(2)(CO(3))(2)(A-alpha-SiW(9)O(34))(2)}(2)].60H(2)O (1) was made by the reactions of trivacant [A-alpha-SiW(9)O(34)](10-) ({SiW(9)}) uni …
A novel tetrahedral mu-AsO(4)-bridging hexadecanuclear Ni-substituted silicotungstate (ST) Na(21)H(10)[(AsO(4)){Ni(8)(OH)(6)(H …
APOC3 siRNA and ASO therapy for dyslipidemia.
Chebli J, Larouche M, Gaudet D. Chebli J, et al. Curr Opin Endocrinol Diabetes Obes. 2024 Apr 1;31(2):70-77. doi: 10.1097/MED.0000000000000857. Epub 2024 Feb 9. Curr Opin Endocrinol Diabetes Obes. 2024. PMID: 38334488 Review.
The main apoC3 inhibitors in advanced clinical development are the GalNAc-ASO olezarsen and the GalNAc-siRNA plozasiran. Clinical studies conducted with volanesorsen, the olezarsen precursor, showed a favorable effect on hepatic steatosis (nonalcoholic fatty liver disease, …
The main apoC3 inhibitors in advanced clinical development are the GalNAc-ASO olezarsen and the GalNAc-siRNA plozasiran. Clinical stu …
11,302 results
You have reached the last available page of results. Please see the User Guide for more information.